$88.4 Million is the total value of M28 Capital Management LP's 14 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BBIO | Sell | BRIDGEBIO PHARMA INC | $5,051,926 | +58.2% | 304,700 | -27.3% | 5.71% | +87.7% |
ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $1,711,960 | -70.7% | 67,400 | -53.2% | 1.94% | -65.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 46.4% |
INVIVYD INC | 8 | Q3 2023 | 32.1% |
ROCKET PHARMACEUTICALS INC | 8 | Q3 2023 | 16.6% |
BRIDGEBIO PHARMA INC | 8 | Q3 2023 | 6.1% |
TG THERAPEUTICS INC | 8 | Q3 2023 | 9.2% |
NEXIMMUNE INC | 8 | Q3 2023 | 0.5% |
STOKE THERAPEUTICS INC | 7 | Q2 2023 | 10.2% |
CURIS INC | 7 | Q2 2023 | 9.7% |
PROQR THRAPEUTICS N V | 7 | Q3 2023 | 6.7% |
ATARA BIOTHERAPEUTICS INC | 5 | Q1 2023 | 5.6% |
View M28 Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adagio Therapeutics, Inc. | August 19, 2022 | 9,248,250 | 8.5% |
View M28 Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-12 |
SC 13G/A | 2024-02-12 |
SC 13G | 2024-02-12 |
4 | 2024-02-08 |
3 | 2024-02-01 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
4 | 2023-05-25 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-02-10 |
View M28 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.